PE23.03 Ten years of the AVAC Advocacy Fellows Program: An evaluationE-posterPolicy and advocacy
PE23.02 Adoption of WHO's HIV retesting policy for HIV-negative women during the breastfeeding period in 10 high HIV-burden African countriesE-posterPolicy and advocacy
PE23.01 Identifying regional disparities in access to HIV and sexual health resources for young men who have sex with men in the United States: The iREACH StudyE-posterPolicy and advocacy
PE22.03 Impact of UGT induction by rifampin and rifabutin on cabotegravir long-acting pharmacokinetics for HIV pre-exposure prophylaxis (PrEP) using population pharmacokinetic modeling and simulationE-posterPharmacology/PK and PD studies
PE22.02 MRI examination of cabotegravir long-acting formulation depot kinetics in healthy adult volunteersE-posterPharmacology/PK and PD studies
PE22.01 Directly Observed Therapy (DOT) can be Implemented Successfully in Research Settings to Evaluate PrEP PK among Pregnant and Postpartum Adolescents and Young Women in AfricaE-posterNovel vaccine and other prevention approaches
PE21.07LB HIV-1 fusion peptide (FP) conjugate and envelope trimer cocktail immunization elicit diverse FP-directed neutralizing antibodies in non-human primatesE-posterNovel vaccine and other prevention approaches
PE21.05LB Immunization with HIV-1 fusion peptide carrier conjugate in a cocktail with HIV-envelope trimer elicits potent and cross-clade neutralization activity in guinea pigsE-posterNovel vaccine and other prevention approaches
PE21.04LB Advances in the use of a bacterially derived glycoside for inducing oligomannose-targeted neutralizing antibodies to HIV-1E-posterNovel vaccine and other prevention approaches
PE21.02 CD40-targeted vaccine increases magnitude of HIV-Env specific responsesE-posterNovel vaccine and other prevention approaches
seek-warrow-warrow-eseek-e111 - 120 of 444 items